Prana has announced that it has filed its Annual Report on Form 20-F
Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology
PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture
Prana AGM webcast
Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"